Skip to main content

Xenon Pharmaceuticals’ stock falls as depression treatment has mixed results in clinical trial

Xenon Pharmaceuticals shares fell early Monday after the company released new clinical-trial data on an experimental depression treatment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.